Serum erythropoietic activity in acute anemia--an animal model

Serum erythropoietic activity and reticulocyte response to anemia were investigated using a rabbit model. In hemolytic anemia, induced by injections of phenylhydrazine on Day 0 the hemoglobin reached a nadir (mean, 6.23 g/dl) on Day 4 when SEA was maximal (mean, 765 mU/ml). In animals venesected on Day 0 and Day 1 to produce anemia of equal severity, the SEA was maximal (mean 235 mU/ml) on Day 2. In both groups the reticulocyte response peaked on Day 7--at 34% for the hemolytic group and 21% for the venesected group. The 2,3-diphosphoglycerate, measured on Day 4, was significantly reduced in the PHZ-treated group. In the venesected group the 2,3-DPG increased between Day 0 and Day 4. There were no concurrent changes in acid-base balance. These results imply that the degree of anemia is only one of the factors which influence the level of circulating SEA.     

Uroporphyrinogen III cosynthetase activity in fibroblasts from patients with congenital erythropoietic porphyria

The activity of uroporphyrinogen III cosynthetase is lower in extracts of fibroblasts from patients with congenital erythropoietic porphyria than in extracts of fibroblasts from control subjects. The porphyric extracts do not inhibit the cosynthetase activity of control extracts. The genetically determined enzymatic defect in this disease can thus occur in other tissues besides bone marrow.Supported in part by a National Institutes of Health Grant (NB-05367).     

Impact of chronic phosalone toxicity on erythropoietic activity of fish, Oreochromis mossambicus.

Effect of multiple sublethal concentrations of Phosalone on whole animal and kidney oxygen consumption, haematological indices and serum enzymes of freshwater fish, Oreochromis mossambicus, were carried out over a 90 day exposure period. Significant changes were observed which have been indicating that the presence of hypoxic condition in the biosystem, gradual increase in the rate of synthesis of haemoglobin and disruption of liver function during the toxicity of phosalone.     

Immunodepressive effect of cell populations with varying erythropoietic activity in embryos and newborn mice

The cells of liver from the 11-12 day old embryos and of spleen from newborn mice were transplanted to adult syngeneic recipients immunized by the ram erythrocytes. The immune response in the recipient spleens was estimated by the number of antibody-forming cells. The cells of embryonic liver and of newborn spleen suppressed the immune response in recipients to a great extent. The immunodepressive effect obtained was similar to suppression due to the transfer of cell populations from the mice in which erythropoiesis was stimulated by hypoxia of phenylhydrazine. The splenocytes of adult control mice and the cells of spleen from 6-9 day old mice did not exert such an effect. The rabbit antiserum to erythroid cells relieved the suppressor effect of the embryonic liver and neonatal spleen cells, as well as of the other erythropoietic populations. A conclusion is drawn on participation of cells-suppressors of the erythroid nature in the mechanisms of immunological non-responsiveness at the early ontogenetic stages in mice.     

Isolation and characterization of a subset of erythropoietin glycoforms with cytoprotective but minimal erythropoietic activity

Although historically used for the treatment of anemia, erythropoietin (EPO) has emerged as a neurotrophic and neuroprotective agent in different conditions of neuronal damage (traumatic brain injury, ischemia, spinal cord compression, peripheral neuropathy, retinal damage, epilepsy, Parkinson's Disease, among others). Nonetheless, EPO's therapeutic application is limited due to its hematological side‐effects. With the aim of obtaining EPO derivatives resembling the hormone isolated from cells and tissues of neural origin, a novel combination of less acidic EPO glycoforms ‐designated as neuroepoetin (rhNEPO)‐ was purified to homogeneity from the supernatant of a CHO‐producing cell line by a four‐step chromatographic procedure. This simple and single process allowed us to prepare two EPO derivatives with distinct therapeutic expectations: the hematopoietic version and a minimally hematopoietic, but mainly in vitro cytoprotective, alternative. Further biological characterization showed that the in vivo erythropoietic activity of rhNEPO was 25‐times lower than that of rhEPO. Interestingly, using different in vitro cytoprotective assays we found that this molecule exerts cytoprotection equivalent to, or better than, that of rhEPO in cells of neural phenotype. Furthermore, despite its shorter plasma half‐life, rhNEPO was rapidly absorbed and promptly detected in the cerebrospinal fluid after intravenous administration in rats (5 min postinjection, in comparison with 30 min for rhEPO). Therefore, our results support the study of neuroepoetin as a potential drug for the treatment of neurological diseases, combining high cytoprotective activity with reduced hematological side‐effects. © 2011 American Institute of Chemical Engineers Biotechnol. Prog., 2011     

Distribution and activity of certain dehydrogenases in the erythropoietic process in pigeons]

Cytochemical methods were applied for detecting of distribution and dynamics of dehydrogenase activity (H- and M-subunits of lactate dehydrogenase, malate and succinate dehydrogenase) during maturation of pigeon erythrocytes. In the erythroblasts the above enzymes were seen in the whole cell; in reticulocytes - only around the nucleus; in erythrocytes - on the border line between the nucleus and the cytoplasm. The cytophotometric data show a decrease in enzymatic activity during maturation being more significant in the period from the erythroblast to reticulocyte development than from the reticulocyte to erythrocyte development.     

Poly(A) polymerase activity during cell cycle and erythropoietic differentiation in erythroleukemic mouse spleen cells.

Poly(A) polymerase activity was studied in lysates of cultured murine erythroleukemic cells (Friend cells). Incorporation of ATP into acid-precipitable products is dependendent on the presence of Mn2+ or Mg2+ and of an RNA primer. The reaction is specific for ATP as the substrate (KM=290 290 micron, it is not inhibited by actinomycin D and only slightly interferred with by ethidium bromide. Cordycepin 5'-triphosphate and sodium pyrophosphate inhibit the enzyme activity. The chain length of the products of the reaction is dependent on the primer concentration and reaches up to 30 nucleotides. Poly(A) polymerase activity is low in resting (G1 phase) cells 75 nmol ATP incorporated/h per 10(6) cells) and increases to a level about twice as high in early S phase of the cell cycle. A possible model for regulation of enzyme activity is discussed. Polymerase activity in the early phase of erythropoietic differentiation of the cells induced by butyric acid does not show any difference in comparison to untreated controls. A decrease in enzyme activity to levels characteristic for cells in G1 phase accompanies shutdown of cell growth in the course of the ongoing differentiation. Analysis of the DNA content of the cells revealed that erythropoietic differentiation of Friend cells induced by butyric acid is characterized by arrest of the cells in G1 phase of the cell cycle. Poly(A) polymerase activity in erythroleukemic cells is thus controlled only by the phase of the cell cycle; it is not affected by changes in gene expression during erythroid differentiation.     

Changes in erythropoietic activity of the rat plasma in the course of posttransfusion polycythaemia

The aim of this study was to determine the erythropoietic activity of the plasma of polycythaemic rats and of one of its protein fractions playing a role in erythropoiesis regulation. The erythropoietin activity and that of the erythropoiesis inhibitor varied in the examined plasma samples at definite time periods after induction of polycythaemia. It was demonstrated that the most suitable time of plasma collection for the inhibitor investigation is the period between 115 and 187 h after the first transfusion, and that in some cases separation of this factor from erythropoietin present simultaneously in the plasma is indispensable in order to reveal the inhibitory activity. The erythropoiesis inhibitor administered jointly with erythropoietin was found to exert no influence on erythropoiesis either in normal or in polycythaemic recipients of the tested plasma.     

Successful gene therapy of mice with congenital erythropoietic porphyria

Porphyrias are a group of disorders due to a genetic deficiency in one of the heme biosynthetic pathway enzymes. Congenital erythropoietic porphyria (CEP) is the most severe type characterized by a deficiency in uroporphyrinogen III synthase (UROS) activity. Bone marrow transplantation represents a curative treatment for patients, as long as human leucocyte antigen-compatible donor is available. We used a recently obtained murine model to check the feasibility of gene therapy in this disease. Lentivirus-mediated transfer of the human UROS cDNA into hematopoietic stem cells (HSCs) from Uros(mut 248) mice resulted in a complete and long-term enzymatic, metabolic and phenotypic correction of the disease, favored by a survival advantage of corrected red blood cells. These results demonstrate for the first time that the cure of this mouse model of CEP at moderate transduction level supports the proof of concept of a gene therapy in this disease by transplantation of genetically modified HSCs.